BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions. The Company purchased 10.5 Bitcoin (BTC) and 300 Ethereum (ETH) for a total of approximately $2.6 million as part of its strategy to strengthen its treasury position and expand its abilit ...

Peter Stazzone Chief Financial Officer, LIXTE Biotechnology Holdings Lourdes Felix Board of Directors, LIXTE Biotechnology Holdings Guy Primus Board of Directors, LIXTE Biotechnology Holdings -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy a ...

-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- Summary of Recent Corporate Activities: Completion of two financings: a private placement with accredited investors, raising aggregate gross procee ...

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has regained compliance with Nasdaq's Listing Rule 5550(b)(1) after successfully closing a $5.0 million placement and a $1.5 million registered direct offering, ensuring its continued listing on the Nasdaq Capital Market [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new areas in cancer drug development [3][4]. - The company's lead clinical compound, LB-100, is a first-in-class PP2A inhibitor that has shown promise in enhancing chemotherapies and immunotherapies for cancer patients [3][4]. Financial Health - The recent capital raises of $5.0 million and $1.5 million have bolstered the company's financial position, allowing it to meet the minimum equity requirement of $2.5 million for Nasdaq compliance [1][2]. - CEO Geordan Pursglove emphasized the company's commitment to maintaining its Nasdaq listing and improving its financial health while pursuing clinical trials for various cancers [3]. Clinical Development - LIXTE is currently conducting proof-of-concept clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma [4]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [4].

Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a registered direct offering, raising approximately $1.5 million through the sale of shares of Common Stock and Pre-Funded Warrants [1][3]. Group 1: Offering Details - The offering included the sale of 974,026 shares of Common Stock or Pre-Funded Warrants, with a public offering price of $1.54 per share [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. - The gross proceeds from the transaction amounted to approximately $1.5 million, and the transaction closed on July 8, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are expected to be used for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead clinical compound, LB-100, which has shown potential in enhancing chemotherapies and immunotherapies [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, and proof-of-concept clinical trials are currently underway for various cancer types [7].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is initiating a pre-clinical study in collaboration with the Netherlands Cancer Institute to explore the potential of its compound LB-100 in eliminating "initiated" cells that carry mutations associated with cancer [1][2]. Group 1: Study Details - The new study will focus on whether LB-100 can eliminate "initiated" cells with a mutant RAS oncogene in animal models, which could significantly reduce the risk of developing various cancers as individuals age [3]. - The study is part of LIXTE's broader strategy to enhance cancer prevention efforts alongside ongoing clinical trials for ovarian and colorectal cancers [2]. Group 2: Leadership and Expertise - The study will be led by Dr. René Bernards, a prominent figure in molecular carcinogenesis and a member of LIXTE's Board of Directors, highlighting the expertise behind the research [4]. Group 3: Company Background - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound LB-100 showing promise in terms of patient tolerance and low toxicity during Phase 1 clinical trials [5][6]. - LB-100 is positioned as a first-in-class PP2A inhibitor, with potential applications in enhancing chemotherapies and immunotherapies for cancer patients [5].